Scientists discover robust evidence that chronic fatigue syndrome is a biological illness

February 27, 2015, Columbia University's Mailman School of Public Health

Researchers at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health identified distinct immune changes in patients diagnosed with chronic fatigue syndrome, known medically as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. The findings could help improve diagnosis and identify treatment options for the disabling disorder, in which symptoms range from extreme fatigue and difficulty concentrating to headaches and muscle pain.

These immune signatures represent the first robust physical evidence that ME/CFS is a biological illness as opposed to a psychological disorder, and the first evidence that the disease has distinct stages. Results appear online in the new American Association for the Advancement of Science journal, Science Advances.

With funding to support studies of immune and infectious mechanisms of disease from the Chronic Fatigue Initiative of the Hutchins Family Foundation, the researchers used immunoassay testing methods to determine the levels of 51 immune biomarkers in blood plasma samples collected through two multicenter studies that represented a total of 298 ME/CFS patients and 348 healthy controls. They found specific patterns in patients who had the disease three years or less that were not present in controls or in patients who had the disease for more than three years. Short duration patients had increased amounts of many different types of immune molecules called cytokines. The association was unusually strong with a cytokine called interferon gamma that has been linked to the fatigue that follows many viral infections, including Epstein-Barr virus (the cause of infectious mononucleosis). Cytokine levels were not explained by symptom severity.

"We now have evidence confirming what millions of people with this disease already know, that ME/CFS isn't psychological," states lead author Mady Hornig, MD, director of translational research at the Center for Infection and Immunity and associate professor of Epidemiology at Columbia's Mailman School. "Our results should accelerate the process of establishing the diagnosis after individuals first fall ill as well as discovery of new treatment strategies focusing on these early blood markers."

There are already human monoclonal antibodies on the market that can dampen levels of a cytokine called interleukin-17A that is among those the study shows were elevated in early-stage patients. Before any drugs can be tested in a clinical trial, Dr. Hornig and colleagues hope to replicate the current, cross-sectional results in a longitudinal study that follows patients for a year to see how cytokine levels, including interleukin-17A, differ within individual patients over time, depending on how long they have had the disease.

Stuck in High Gear

The study supports the idea that ME/CFS may reflect an infectious "hit-and-run" event. Patients often report getting sick, sometimes from something as common as (Epstein-Barr virus), and never fully recover. The new research suggests that these infections throw a wrench in the 's ability to quiet itself after the acute infection, to return to a homeostatic balance; the becomes like a car stuck in high gear. "It appears that ME/CFS patients are flush with cytokines until around the three-year mark, at which point the immune system shows evidence of exhaustion and cytokine levels drop," says Dr. Hornig. "Early diagnosis may provide unique opportunities for treatment that likely differ from those that would be appropriate in later phases of the illness."

The investigators went to great lengths to carefully screen participants to make sure they had the disease. The researchers also recruited greater numbers of patients whose diagnosis was of relatively recent onset. Patients' stress levels were standardized; before each blood draw, patients were asked to complete standardized paperwork, in part to engender fatigue. The scientists also controlled for factors known to affect the immune system, including the time of day, season and geographic location where the samples were taken, as well as age, sex and ethnicity/race.

In 2012, W. Ian Lipkin, MD, director of the Center for Infection and Immunity, and colleagues reported the results of a multicenter study that definitively ruled out two viruses thought to be implicated in ME/CFS: XMRV (xenotropic murine leukemia virus [MLV]-related virus) and murine retrovirus-like sequences (designated pMLV: polytropic MLV). In the coming weeks, Drs. Hornig and Lipkin expect to report the results of a second study of cerebrospinal fluid from ME/CFS patients. In separate ongoing studies, they are looking for "molecular footprints" of the specific agents behind the disease—be they viral, bacterial, or fungal—as well as the longitudinal look at how plasma cytokine patterns change within ME/CFS patients and controls across a one-year period, as noted above.

"This study delivers what has eluded us for so long: unequivocal evidence of immunological dysfunction in ME/CFS and diagnostic biomarkers for disease," says senior author W. Ian Lipkin, MD, also the John Snow Professor of Epidemiology at Columbia's Mailman School. "The question we are trying to address in a parallel microbiome project is what triggers this dysfunction."

Explore further: New study finds chronic fatigue syndrome not linked to XMRV and pMLV viruses

More information: Distinct plasma immune signatures in ME/CFS are present early in the course of illness, advances.sciencemag.org/content/1/1/e1400121

Related Stories

New study finds chronic fatigue syndrome not linked to XMRV and pMLV viruses

September 18, 2012
The causes of chronic fatigue syndrome (CFS) have long eluded scientists. In 2009, a paper in the journal Science linked the syndrome—sometimes called myalgic encephalomyelitis (ME)—to infection with a mouse retrovirus ...

New IOM report identifies five symptoms to diagnose chronic fatigue syndrome

February 10, 2015
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome—commonly referred to as ME/CFS—is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, ...

New name, new criteria for chronic fatigue syndrome?

February 10, 2015
(HealthDay)—Chronic fatigue syndrome, a debilitating illness affecting up to 2.5 million Americans, may soon get a new name and set of diagnostic criteria.

Toward a clearer diagnosis of chronic fatigue syndrome

April 4, 2014
Researchers at the RIKEN Center for Life Science Technologies, in collaboration with Osaka City University and Kansai University of Welfare Sciences, have used functional PET imaging to show that levels of neuroinflammation, ...

Brain neuroinflammation seen in chronic fatigue syndrome

April 11, 2014
(HealthDay)—Neuroinflammation markers are elevated in the brains of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) patients compared to healthy controls, according to a study published online March 24 in the ...

Discovery could lead to faster diagnosis for some chronic fatigue syndrome cases

November 14, 2012
For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome (CFS), a complex disorder with no known definitive cause or cure.

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

sashathornton24
not rated yet Feb 28, 2015
Thank you for covering this important topic and to the CII team for their dedication to some of the most neglected patients in medical history.

At least a million Americans suffer from this disease, many severely disabled and in pain. So many lives in ruins and yet the NIH spends a paltry $5m a year on biomedical research.

It's time for this to change! The scientists are raring to go. They just need the money.

Please donate to ME/CFS biomedical research, including to the CII (find the link by going to microbediscovery [dot] org and clicking the donation link).

Please email the NIH and put pressure on them for more funding.

And please email your congressperson and ask them to be the one to stand up and fight for us!

The research wagon is starting to roll. Let's all push it!
greenslopes
not rated yet Mar 01, 2015
I hope the results from this initial research on CFS helps lead to further substantial funding to further understand this condition and develop protocols and products that can the millions of suffers with this horrendous disease

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.